Cite
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
MLA
Porte, Fanny, et al. “Cost-Effectiveness of Avelumab First-Line Maintenance Therapy for Adult Patients with Locally Advanced or Metastatic Urothelial Carcinoma in France.” PLoS ONE, vol. 19, no. 5, May 2024, pp. 1–20. EBSCOhost, https://doi.org/10.1371/journal.pone.0302548.
APA
Porte, F., Granghaud, A., Chang, J., Kearney, M., Morel, A., Plessala, I., Cawston, H., Roiz, J., Xiao, Y., Solbes, M.-N., Lambert, P., Ravaud, A., Loriot, Y., Thiery-Vuillemin, A., & Lévy, P. (2024). Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France. PLoS ONE, 19(5), 1–20. https://doi.org/10.1371/journal.pone.0302548
Chicago
Porte, Fanny, Anna Granghaud, Jane Chang, Mairead Kearney, Aya Morel, Ingrid Plessala, Hélène Cawston, et al. 2024. “Cost-Effectiveness of Avelumab First-Line Maintenance Therapy for Adult Patients with Locally Advanced or Metastatic Urothelial Carcinoma in France.” PLoS ONE 19 (5): 1–20. doi:10.1371/journal.pone.0302548.